We are pleased to announce that Kaoru Komatsu (CTO of xFOREST Therapeutics Co., Ltd.) released the research on fluid flow-dependent mRNA degradation mechanism that determines the left-right asymmetry of the animal body. Komatsu and his previous colleagues in Hirohide Saito lab performed massive RNA-protein interaction analysis with a randomized RNA library to determine protein-binding motifs.
The paper has been published in Nature Communications.
Title: Fluid flow-induced left-right asymmetric decay of Dand5 mRNA in the mouse embryo requires a Bicc1-Ccr4 RNA degradation complex
Authors: Katsura Minegishi*, Benjamin Rothé*, Kaoru R. Komatsu*, Hiroki Ono, Yayoi Ikawa, Hiromi Nishimura, Takanobu A. Katoh, Eriko Kajikawa, Xiaorei Sai, Emi Miyashita, Katsuyoshi Takaoka, Kana Bando, Hiroshi Kiyonari, Tadashi Yamamoto, Hirohide Saito, Daniel B. Constam & Hiroshi Hamada**
*First Author, **Corresponding Author
Click here for more information(Center for iPS Cell Research and Application, Kyoto University )
Click here for more information (Nature Communications)
About xFOREST Therapeutics
xFOREST Therapeutics Co., Ltd. is a Kyoto-based biotechnology company engaged in the research and development of RNA-targeted small-molecule medicines. Building on its proprietary RNA structure analysis technology, xFOREST discovers selective small molecules for RNA targets that protein-first discovery cannot reach, and advances them into drug programs with partners.